文献速递肝病消化道肿瘤与早癌

脂肪性肝病中胃肠道癌症风险:MASLD、MetALD与ALD

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD, MetALD and ALD.
PubMed 文献 · Aliment Pharmacol Ther · 2025-11-15

结果显示各SLD亚组肝细胞癌和胆道癌风险显著升高,食管癌、胃癌和结直肠癌风险随酒精摄入增加而升高,胰腺癌风险与对照相当。

要点

  • MASLD、MetALD和ALD患者肝细胞癌及胆道癌风险均显著高于对照。
  • 食管癌、胃癌和结直肠癌风险随酒精摄入增加而升高,ALD组最高。
  • MetALD和ALD患者胰腺癌风险与对照相当。

核心结论

  • 脂肪性肝病包括MASLD、MetALD和ALD患者相比对照人群胃肠道癌症风险显著升高,风险程度因肝病亚型而异,尤其与酒精摄入相关。

主要发现

  • 相比对照,肝细胞癌调整风险比在MASLD、MetALD和ALD中为3.55至5.39,胆道癌为1.45至1.66。
  • 食管癌、胃癌和结直肠癌的调整风险比在MASLD中为0.75至1.26,MetALD中为1.09至1.44,ALD中为1.13至2.48。
  • MetALD和ALD患者胰腺癌风险与对照相当。

临床怎么用

  • 对脂肪性肝病患者应实施风险分层的癌症筛查策略,尤其关注酒精摄入较高的MetALD和ALD患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Steatotic liver disease (SLD), which encompasses metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD) and alcohol-associated liver disease (ALD), is recognised as a risk factor for gastrointestinal cancers. However, the comparative risk of gastrointestinal cancers among MASLD, MetALD and ALD remains unclear. METHODS: We used a Japanese, nationwide, health insurance claims database between 2005 and 2024, encompassing approximately 10 million individuals and conducted a nationwide, population-based cohort study including 978,607 patients with MASLD, 366,152 with MetALD, 152,721 with ALD and 4,884,398 control individuals. The primary outcome was the incidence of gastrointestinal cancers, including hepatocellular carcinoma (HCC), biliary tract cancer, oesophageal cancer, gastric cancer, colorectal cancer and pancreatic cancer. RESULTS: Compared to controls, the adjusted hazard ratios (HRs) for HCC ranged from 3.55 to 5.39 across the MASLD, MetALD and ALD and from 1.45 to 1.66 for biliary tract cancer. The risks of both HCC and biliary tract cancer were significantly elevated in all SLD subgroups compared to controls. For oesophageal, gastric and colorectal cancers, the aHRs ranged from 0.75 to 1.26 in MASLD, from 1.09 to 1.44 in MetALD and from 1.13 to 2.48 in ALD, indicating increasing risk with greater alcohol consumption. The risk of pancreatic cancer was comparable to that in controls for both MetALD and ALD. CONCLUSIONS: Patients with SLD, including MASLD, MetALD and ALD, have a significantly higher risk of gastrointestinal cancers compared to the controls. The degree of risk varies according to the underlying liver disease subtype, particularly in relation to alcohol consumption. These findings underscore the importance of implementing risk-stratified cancer screening strategies in patients with SLD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tamaki N, Kimura T, Wakabayashi SI, et al. Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD, MetALD and ALD. Aliment Pharmacol Ther. 2025. PMID: 41240017. doi:10.1111/apt.70466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。